Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Stock investors purchased 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MRVI. Philosophy Capital Management LLC bought a new position in Maravai LifeSciences in the first quarter valued at approximately $5,731,000. Tejara Capital Ltd increased its stake in Maravai LifeSciences by 257.8% in the second quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock valued at $4,679,000 after acquiring an additional 1,398,900 shares during the last quarter. 12 West Capital Management LP increased its stake in Maravai LifeSciences by 8.0% in the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock valued at $27,672,000 after acquiring an additional 930,000 shares during the last quarter. Deutsche Bank AG increased its stake in Maravai LifeSciences by 67.6% in the first quarter. Deutsche Bank AG now owns 2,072,239 shares of the company’s stock valued at $4,580,000 after acquiring an additional 835,600 shares during the last quarter. Finally, First Pacific Advisors LP bought a new position in Maravai LifeSciences in the second quarter valued at approximately $1,787,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Stock Up 2.3%

Shares of MRVI opened at $3.14 on Friday. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $8.29. The firm’s 50 day moving average is $2.90 and its 200-day moving average is $2.50. The stock has a market capitalization of $801.83 million, a PE ratio of -2.31 and a beta of 0.33. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MRVI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada lowered their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.